Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19559756 | 0.89 | PPARG (0.52) | PPARGFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL19217776 | 0.89 | PPARG (0.52) | PPARGFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL19559778 | 0.88 | PPARG (0.38) | PPARGFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL19559725 | 0.84 | PPARG (0.40) | PPARGFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL12628139 | 0.81 | PPARG (0.61) | PPARGFFAR1 | |
| SCHEMBL19559724 | 0.81 | GLA (0.42) | PPARGFFAR1MCL1GLASMN1; SMN2 | |
| SCHEMBL19217722 | 0.78 | PPARG (0.37) | PPARGFFAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL19559726 | 0.78 | PPARG (0.49) | PPARGFFAR1MCL1 | |
| SCHEMBL19559692 | 0.77 | FFAR1 (0.41) | PPARGFFAR1MCL1 | |
| SCHEMBL19559754 | 0.77 | FFAR1 (0.41) | PPARGFFAR1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |